Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 6/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 4/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12169323 | 0.73 | KMT2A (0.57) | LMNAMAPTPOLBKMT2ACA12 | |
| SCHEMBL25980160 | 0.73 | NPC1 (1.00) | TP53LMNAMAPTPOLBNPC1 | |
| SCHEMBL972519 | 0.70 | TP53 (0.62) | TP53MAPTPOLBTDP1NPC1 | |
| SCHEMBL13814487 | 0.69 | KMT2A (0.43) | TP53LMNAMAPTPOLBKMT2A | |
| SCHEMBL25350664 | 0.67 | TP53 (0.82) | TP53LMNAMAPTPOLBNPC1 | |
| SCHEMBL12483715 | 0.67 | KMT2A (0.41) | TP53POLBKMT2ACA12CA9 | |
| SCHEMBL25980233 | 0.66 | CA12 (0.62) | TP53LMNAMAPTPOLBTDP1 | |
| SCHEMBL12498922 | 0.65 | CA12 (0.61) | TP53LMNAMAPTPOLBTDP1 | |
| SCHEMBL28429688 | 0.65 | KMT2A (0.50) | LMNAMAPTPOLBTDP1KMT2A | |
| SCHEMBL19399052 | 0.65 | NPC1 (0.62) | TP53LMNAMAPTNPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015065-A1 | Substituted Sulfonic Acid Amide Compounds | BASF SE (DE) | 2011-01-20 | — | — | US | claimed |
| EP-2252590-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2010-11-24 | — | — | EP | claimed |
| WO-2009101082-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2009-08-20 | — | — | WO | claimed |
| US-20110015065-A1 | Substituted Sulfonic Acid Amide Compounds | BASF SE (DE) | 2011-01-20 | — | — | US | disclosed |
| EP-2252590-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009101082-A1 | SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS | BASF SE (DE) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015065-A1 | Substituted Sulfonic Acid Amide Compounds | STS, NAPA, NAAA | TP53 783/4885LMNA 3828/4885MAPT 3640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.